ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin L
July 22, 2021Antengene announced that the Bellberry Human Research Ethics Committee (HREC) in Australia has approved the clinical trial application of the phase 1 trial of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. -
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
July 02, 2021I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced multiple advancements in its 4-1BB bispecific antibody portfolio.
Pharma Sources Insight January 2025
